<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00289809</url>
  </required_header>
  <id_info>
    <org_study_id>ONC-2005-001</org_study_id>
    <secondary_id>EUDRACT 2005-004569-40</secondary_id>
    <nct_id>NCT00289809</nct_id>
  </id_info>
  <brief_title>TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients</brief_title>
  <official_title>A Perspective Phase I and II Trial of Liposome-encapsulated Doxorubicin (TLC D-99) in Combination With Ifosfamide in Patients With Metastatic Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose of the TLC D-99 combined
      with ifosfamide and then the efficacy of this combination in terms of overall response rate,
      time to progression and time of response
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Maximum Tolerated Dose of the combination was determined and the Phase I terminated.

      Then, Phase II study started.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Maximum Tolerated Dose (MTD) of combination of TLC D-99 and Ifosfamide</measure>
    <time_frame>Definition of TDL</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Response rate (CR/PR or SD)</measure>
    <time_frame>Tumor assessment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II: time to progression, duration of response, overall survival</measure>
    <time_frame>Tumor assessment, follow-up</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Sarcoma, Soft Tissue</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>combination of TLC D-99 and Ifosfamide</intervention_name>
    <description>TLC D-99: 40 mg/m2 Day 1 every 3 weeks;
Ifosfamide: 3000 mg/m2 Day 1, 2, 3 every 3 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic diagnosis of soft tissue sarcoma metastatic or recurrent after 6 months
             from the last chemotherapy

          -  Age &gt;/=18 yrs

          -  PS &lt;/=2

          -  Disease detectable almost for 1 dimension

          -  Life expectancy &gt;/=3 mos

          -  Minimum 4 wks from last radiotherapy

          -  Adequate medullary, liver, and renal functions

          -  Normal LVEF

          -  Written Informed Consent

        Exclusion Criteria:

          -  Pregnant or breast-feeding patients

          -  Serious concomitant disease or not controlled infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando Santoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2006</study_first_submitted>
  <study_first_submitted_qc>February 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2006</study_first_posted>
  <last_update_submitted>December 17, 2009</last_update_submitted>
  <last_update_submitted_qc>December 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Armando Santoro</name_title>
    <organization>Istituto Clinico Humanitas</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

